Abstract: Circulating microRNAs have the potential to be noninvasive biomarkers for assessing disease progression. MicroRNA-551b-5p (miR-551b-
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Due to its systemic complications, severe acute pancreatitis (SAP) has high mortality, and the early assessment of the severity is important for following treatment (1) . It entails intensive management of renal, pulmonary, cardiovascular, and septic complications (2) . A population-based cohort study revealed that pyogenic liver abscess (PLA) correlates with the increased risk of subsequent acute pancreatitis (AP) (3) , and a nationwide cohort study demonstrated a 51% increased risk of AP following infection with pneumococcal pneumonia (4). In the following year, another case-control study by the same author reported that splenectomy is associated with AP (5). Although many attempts have been made to develop physical and radiologic scoring systems with an aim of predicting the severity of clinical course in different patients (6, 7) , due to its complexity, it is not easy to assess the disease accurately. Therefore, the development of an auxiliary prognostic marker along with clinical and radiological scores is needed.
Micro RNAs (miRNAs) are small, noncoding RNA fragments that are implicated in post-transcriptional regulation either by repressing Messenger RNA (mRNA) translation into proteins or by promoting mRNA degradation (8) . Recent studies suggest that miRNAs in plasma or serum can be steadily detected and applied as diagnostic and prognostic markers in disease (9) . In a previous study, miR-155 has been involved in inflammatory responses (10, 11) , which usually appear at the relatively early stage of SAP progression. It has also been proposed that miR-551b-5p may help in the stratification of patient with AP as endothelial dysfunction during AP is reflected by levels of miR-551b-5p (12) . In another bioinformatics analysis, the potential value of miR-551b-5p has been implicated in predicting AP severity. However, to the best of our knowledge, the clinical significance of serum miR-551b-5p levels in patients with MAP and SAP has not been intensively studied. The aim of this study, therefore, was to examine serum miR-551b-5p levels in patients with mild and SAP and to elucidate the underlying mechanism regarding inflammatory response during disease progression.
PATIENTS AND MATERIALS

Patient specimen collection
In accordance with the clinical severity scores (MODS [multiple organ dysfunction score] >2; Imrie-Glasgow>2; APACHE II [acute physiology and chronic health evaluation II] >7), patients were classified into MAP and SAP groups (13, 14 APACHE II, MODS, sequential organ assessment score (SOFA), and Ranson's scores were determined on admission. The SOFA score was continuously recorded on a weekly basis during the Intensive Care Unit (ICU) stay. The mean, highest, and initial SOFA scores were considered for following analysis.
PBMCs isolation
Peripheral blood mononuclear cells (PBMCs) were freshly isolated from the 93 participants and stored at −80 C for subsequent use. Blood samples were collected subjected to following PBMCs isolation on days 1, 3, and 5 after the symptom start, while blood from healthy controls was only obtained once.
In brief, after being collected, the whole blood samples were centrifuged at 1600 Relative Centrifugal Field (RCF) at 20 C for 30 min. The plasma was removed, and the buffy coat presenting PBMCs was transferred into a new tube and filled with phosphate-buffered saline (PBS) until a total volume of 15 mL was obtained and centrifuged again at 300 RCF at 20 C for 15 min. After the removal of the supernatant, the pellets were subjected to resuspension in PBS (10 mL) followed by centrifugation at 20 C for 15 min. After removing the supernatant again, PBMCs underwent resuspension in freeze media (10% dimethylsulfoxide, 20% fetal bovine serum in RPMI media) and were finally transferred into cryovials and maintained at −140 C until lysis.
Cell transfection
The miR-551b-5p-negative controls and inhibitors were purchased from Qiagen (Germantown, MD, USA). For control, AllStars negative mimics (Qiagen) were used. Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) was performed for transient transfections, followed by manufacturer's guidance. PBMCs were transfected and reached a final concentration of 100 nM.
H&E staining
Paraffin-embedded samples were prepared using surgically obtained tissue specimens from 10 SAP and 3 MAP patients who underwent pancreatic resection. Pancreatic sections were stained with hematoxylin and eosin.
Quantitative real-time PCR
Total RNA was extracted from 5 mL of blood samples obtained from each patient using the mirPremier miRNA isolation kit (Sigma-Aldrich, St. Louis, MO, USA). RNA was transcribed into cDNA using the reverse transcription kit (Tiangen Biotech Beijing CO., LTD., Beijing, China). MiR-551b-5p was detected using reverse transcription primers, and as an internal control, U6 was used. Primers were synthesized from the Beijing Tiangen Biochemical Division Technology Co., Ltd. Quantitative real-time polymerase chain reaction (RT-PCR) was performed using the TaqMan Advanced miRNA assays (Thermo Fisher, Waltham, MA, USA), and 7900HT sequence detection system (Applied Biosystems) was used for quantification. Cycling conditions were 95 C for 5 min for preheating followed by 40 cycles of 95 C for 15 s and 60 C for 60s. All PCR reactions were performed in triplicate. Expression levels of miR-551b-5p were calculated relative to U6 mRNA using Equation 2
−ΔCt .
ELISA
Collected serum samples were stored at −70 C. Inflammatory cytokines, IL-6, IL-17, IL-1β, and TNF-α, were measured by using commercially available ELISA kits in accordance with the manufacturer's guidance (JRDUN, Shanghai, China).
Statistical analysis
The Mann-Whitney and chi-square tests were used when appropriate. The SPSS for Windows (version 19.0.) statistical package was used. A Pvalue below 0.05 was considered statistically significant. Data are presented with mean AE SD and/or median Interquartile Range (IQR).
RESULTS
Severity of enrolled patients and miR-551b-5p expression Different scoring systems were used for measurements in the SAP, MAP, and healthy control (HC) patients. Data were presented as median AE SD (interquartile range). Demographic information and clinical characteristics of the study population are shown in Table 1 Histological observation was carried out in patients from different groups. In MAP patients, acinar atrophy with intralobular fibrosis was observed. In SAP patients, the enclosed acini appeared to be atrophic and were surrounded by fibrotic bands. The collagen in areas of fibrosis were strongly stained Sirius Red (Figure 1) .
Our quantitative RT-PCR analysis exhibited that miR-551b-5p mRNA levels in tissues of SAP and MAP patients was significantly elevated compared with those of healthy controls (P < 0.001) ( Figure 1B ). This trend was observed in isolated PBMCs from different patients ( Figure 1C ).
MiR-551b-5p level is correlated with the severity of pancreatitis
Data regarding miR-551b-5p expression levels in patients with pancreatitis are shown in Figure 2 . Patients with high APACHE II, MODS, SOFA, and Ranson's scores had significantly higher serum miR551b-5p levels than those with low APACHE II, MODS, SOFA, and Ranson's scores (P < 0.001). There were significant positive correlations between miR-551b-5p level and Ranson's score (r = 0.8350, P < 0.001), APACHE II score (r = 0.9293, P < 0.001), MODS score (r = 0.8399, P < 0.001), and SOFA score (r = 0.7606, P < 0.001).
Expression of inflammatory cytokines in MAP and SAP patients at different time points
We compared changes in inflammatory response (IL-6, IL-17, IL-1 β, and TNF-α) between MAP, SAP, and healthy controls on days 1, 3, and 5 (Figure 3) . High serum levels of IL-6, IL-17, IL-1 β, and TNF-α were found on day 1 in both MAP and SAP patients compared with healthy controls (P < 0.05). These concentrations, however, were reduced and normalized by the length of hospital stay, which is reflected by the reduced level of IL-6, IL-1 β, and IL-17 on day 3 and day 5. TNF-α showed a trend toward reduction but remained significantly elevated.
Expression of inflammatory cytokines in the presence or absence of miR-551b-5p in PBMCs isolated from SAP and healthy controls
To elucidate the impact of miR-551b-5p on the expression of inflammatory cytokines, PBMCs isolated from SAP patients were transfected with an miR-551b-5p inhibitor. Our results showed that expression levels of IL-6, IL-17, IL-1 β, and TNF-α in PBMCs isolated from SAP patients were remarkably elevated in comparison with those of healthy controls (P < 0.05). In the SAP group, expression levels of IL-6, IL-17, IL-1 β, and TNF-α in cells transfected with miR-551b-5p inhibitor were significantly reduced compared to cells transfected with the miR551b-5p-negative control (P < 0.05) (Figure 4 ).
DISCUSSION
In this study, we found that the serum miR-551b-5p level is elevated in MAP and SAP patients. Moreover, the miR-551b-5p level is associated with disease severity, which is reflected by the significant correlation of the miR-551b-5p mRNA level with APACHE II, SOFA, MODS, and modified Ranson's scores. We also found that expression levels of inflammatory cytokines were gradually reduced over the length of ICU stay. In order to investigate the effect of miR-551b-5p on immune response, PBMCs isolated from SAP patients were transfected with an miR-551b-5p inhibitor, and the immunoregulation was evaluated after transfection. Results showed that elevated level of inflammatory cytokines was associated with elevated level of miR551b-5p in SAP patients.
In previous bioinformatic analysis, upregulated miR-551b-5p was screened out in celiac disease (15) and AP (16) . These findings have established a fundamental purpose for following functional studies. Increased miR-551b-5p expression was shown to lead to endothelial dysfunction by upregulating Egr-1 expression (17) . The diagnostic and prognostic value of miR-551b-5p has been studied in acute pancreatic patients (12) . Maintaining consistency with the above literature, our results showed that the serum miR-551b-5p level is elevated in MAP and SAP patients.
Various scoring systems established on admission to the ICU have been used to distinguish high-risk patients (18) (19) (20) . APACHE II, MODS, SOFA, and Ranson's scores are the most commonly used scoring systems. The Atlantic classification of SAP was established to enable the direct comparison of results obtained from different scoring systems (21) . Although these scoring systems are useful for the comprehensive evaluation and risk stratification of acute pancreatic patients, the process requires information regarding many aspects of the disease. In most of the cases, it is difficult to implement such a complicated evaluation procedure in the setting of emergency medicine. Thus, a need arises to develop novel biomarkers with high efficiency and accuracy for predicting the severity of AP. Our results demonstrated that a high serum level of miR-551b-5p is positively correlated with APACHE II, MODS, SOFA, and Ranson's scores. These results suggest that the serum miR-551b-5p level can be valuable in determining the severity of AP.
Serum concentrations of various inflammatory markers and mediators, for example, proinflammatory cytokines, procalcitonin, or acute phase proteins, vary between MAP and SAP patients and may help in clinical practice (22) (23) (24) (25) . The severity of AP patients shifted from mild to SAP usually after 24 h of disease admission. Hence, it was conjectured   FIG. 3 . Level of inflammatory factors in serum sample (ng/l). Protein content of (A) IL-6, (B) IL-1β, (C) IL-17, (D) TNF-α) and TNF-α in serum samples from mild acute pancreatitis (MAP), severe acute pancreatitis (SAP) patients, and healthy control using ELISA kits. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control, #P < 0.05 vs. MAP on day 1.
FIG. 4.
Level of (A) IL-6, (B) IL-1β, (C) IL-17, (D) TNF-α in peripheral blood mononuclear cells (PBMCs) after transfection with miR-551b-5p inhibitor (inhibitor) using ELISA kits. **P < 0.01, ***P < 0.001 vs. control, ##P < 0.01 vs. severe acute pancreatitis (SAP).
that the expression of these inflammatory cytokines cannot indicate the progression and consequence of the AP satisfactorily due to their short half-life. Noncoding RNAs, especially miRNAs, have emerged as important transcriptional regulators of some inflammation-related mediators (26) . It is possible that miRNAs can regulate the expression of inflammatory cytokines during the progression of MAP to SAP. Studies have proven that inflammation can be caused by stimulation of cytokines, such as IL-1β, IL-6, and TNF-α (27, 28) . A study demonstrated that the knockout of miR-21 reduces inflammatory cell infiltrate to the pancreas during cerulein-induced pancreatitis (29) . The inflammatory regulator miR-30a-5p was upregulated by emodin in pancreatic acinar cells, and the pancreatic protective effects and anti-inflammatory activities of emodin were all abrogated with miR-30a-5p inhibition both in vitro and in vivo, where altered expression of TNF-α, IL-1β, and IL-6 was involved (30) . In the present study, we also found that the expression levels of these inflammatory cytokines (IL-6, IL-17, IL-1 β, and TNF-α) were significantly increased in the presence of miR-551b-5p in SAP patients. Therefore, we speculate that miR-551b-5p may be associated with an inflammatory response in acute pancreatic patients.
CONCLUSION
Serum miR-551b-5p is elevated in severe acute pancreatitis (SAP) patients, and may be a useful biomarker for distinguishing between mild to SAP. In addition, the elevated level of miR-551b-5p is associated with inflammation in acute pancreatitis. Large-scale prospective studies are required to confirm our findings.
